- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
DFS, OS Benefit Maintained With Adjuvant Atezolizumab vs BSC in Stage II/IIIA NSCLC
June 3rd 2024, 8:58pm
Long-term DFS and OS outcomes with adjuvant atezolizumab in stage II to IIIA NSCLC were consistent with prior data from the IMpower010 trial.
KIM-1 Shows Prognostic and Predictive Value With Adjuvant Atezolizumab in RCC
June 3rd 2024, 6:49pm
Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease (MRD), disease recurrence, and benefit from adjuvant atezolizumab (Tecentriq) in patients with renal cell carcinoma (RCC) at increased risk of recurrence.
Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC
June 3rd 2024, 6:16pm
Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.
CRS, ICANS Incidence Reduced to Zero Following Tocilizumab, Teclistamab Administration in R/R Multiple Myeloma
June 3rd 2024, 5:17pm
Tocilizumab plus teclistamab step-up dosing showed efficacy and a mainly mild safety profile in patients with relapsed/refractory multiple myeloma.
Belantamab Mafodotin Plus BVd Produces PROs Comparable to DVd in Relapsed/Refractory Multiple Myeloma
June 3rd 2024, 4:50pm
Treatment with BVd elicited PROs comparable with those who were treated with DVd in relapsed/refractory multiple myeloma.
PRO Data Add to Efficacy and Safety of Frontline Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Carcinoma
June 3rd 2024, 4:15pm
Enfortumab vedotin plus pembrolizumab did not negatively affect quality of life in patients with advanced urothelial carcinoma.
Exploring Newly Released Data in GU and GI Cancers: Drs Grivas and Marshall
June 3rd 2024, 2:29pm
OncLive News Network: On Location at ASCO 2024
OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Decreased Azacitadine Dosing Shows Consistent Safety in Lower- and Intermediate-Risk MDS
June 3rd 2024, 1:00pm
Treatment with a decreased dosing schedule of oral azacitidine was consistent with what has been previously known about the agent in intermediate-risk myelodysplastic syndrome.
Belantamab Mafodotin Significantly Extends PFS vs Daratumumab in Myeloma
June 2nd 2024, 11:00pm
Belantamab mafodotin plus bortezomib and dexamethasone improved median progression-free survival vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Dr Vogel on Updated OS Data for Frontline Camrelizumab Plus Rivoceranib in Unresectable HCC
June 2nd 2024, 9:34pm
Arndt Vogel, MD, on the final overall survival data for camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.
Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC
June 2nd 2024, 8:06pm
Suresh S. Ramalingam, MD, FACP, FASCO, discusses findings with osimertinib after definitive chemoradiotherapy in unresectable EGFR-mutated NSCLC.
First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC
June 2nd 2024, 6:54pm
Rivoceranib plus camrelizumab maintained a survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.
Addition of Atezolizumab to Chemotherapy and Bevacizumab Does Not Yield Benefit in Ovarian Cancer
June 2nd 2024, 6:48pm
The addition of atezolizumab to bevacizumab and chemotherapy did not significantly improve overall survival or progression-free survival in patients with recurrent ovarian cancer.
Liver Transplantation Plus Chemotherapy Improves 5-Year OS Rate in Patients With CRC Liver Metastases
June 2nd 2024, 6:01pm
Integrating liver transplantation into treatment with chemotherapy improved survival at 5 years vs chemotherapy alone in patients with definitively unresectable CRC liver metastases.
mIF Biomarker Not Associated With Improved Outcomes With Nivolumab/Ipilimumab Treatment in Metastatic Clear Cell RCC
June 2nd 2024, 5:49pm
Using CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative TILs as a biomarker was not associated with improved clinical outcomes for patients with mccRCC treated with nivolumab plus ipilimumab.
Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC
June 2nd 2024, 5:21pm
Taletrectinib demonstrated high response rates and a tolerable safety profile in patients with ROS1-positive non–small cell lung cancer.
Nivolumab/Ipilimumab Bests Nivolumab in Ovarian and Extra-Renal Clear Cell Carcinomas
June 2nd 2024, 5:12pm
The combination of nivolumab and ipilimumab improved responses as well as survival outcomes in patients with ovarian or gynecologic clear cell carcinomas.
Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer
June 2nd 2024, 5:05pm
Trastuzumab deruxtecan improved PFS vs chemotherapy in pretreated, HR-positive, HER2-low or -ultralow metastatic breast cancer.
Zanidatamab Shows Durable Responses With Longer Follow-up in Pretreated HER2+ Biliary Tract Cancer
June 2nd 2024, 3:58pm
Zanidatamab continued to show confirmed responses, disease control, and prolonged overall survival in pretreated HER2+ biliary tract cancer.
Cabazitaxel/Abiraterone Combination Prolongs PFS vs Abiraterone in mCRPC
June 2nd 2024, 1:42pm
Cabazitaxel plus abiraterone acetate and prednisone improved PSA response and extended PFS vs abiraterone acetate and prednisone in patients with mCRPC.